Cytek Biosciences outlines $205M-$212M 2026 revenue target amid record Q4 and growth in recurring revenue
Source: SeekingAlpha
2026-02-26 20:58:30 ET
More on Cytek Biosciences
- Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
- Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Seeking Alpha’s Quant Rating on Cytek Biosciences
- Historical earnings data for Cytek Biosciences
Read the full article on Seeking Alpha
For further details see:
Cytek Biosciences outlines $205M–$212M 2026 revenue target amid record Q4 and growth in recurring revenue
Cytek Biosciences Inc.
NASDAQ: CTKB
CTKB Trading
-5.22% G/L:
$4.175 Last:
222,461 Volume:
$4.27 Open:
CTKB Latest News
February 26, 2026 04:05:00 pm
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
February 18, 2026 04:05:00 pm
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
CTKB Stock Data
$553,654,714
114,656,393
9.13%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Fremont
